Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2024 · second_quarter · 2A
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria
Source: Senate LDA
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Tax Relief for American Families and Workers Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Tax Relief for American Families and Workers Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Tax Relief for American Families and Workers Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Tax Relief for American Families and Workers Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Tax Relief for American Families and Workers Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Tax Relief for American Families and Workers Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Creating Hope Reauthorization Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
National Computer Forensics Institute Reauthorization Act of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
National Computer Forensics Institute Reauthorization Act of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
National Computer Forensics Institute Reauthorization Act of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
National Computer Forensics Institute Reauthorization Act of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
National Computer Forensics Institute Reauthorization Act of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
National Computer Forensics Institute Reauthorization Act of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Expressing the profound sorrow of the House of Representatives on the death of the Honorable Dianne Goldman Berman Feinstein.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
H. Res. 742- AADC Deficiency Awareness Day
Expressing the profound sorrow of the House of Representatives on the death of the Honorable Dianne Goldman Berman Feinstein.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
H. Res. 742- AADC Deficiency Awareness Day
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
American Innovation and R&D Competitiveness Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to the Orphan Drug Tax Credit; H.R. 1304 -American Innovation and R&D Competitiveness Act of 2021
American Innovation and R&D Competitiveness Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to the Orphan Drug Tax Credit; H.R. 1304 -American Innovation and R&D Competitiveness Act of 2021
Huntington’s Disease Disability Insurance Access Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntington's Disease Disability Insurance Access Act of 2021
Huntington’s Disease Disability Insurance Access Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntington's Disease Disability Insurance Access Act of 2021
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
New Overages in Crisis Areas Prevention Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
To regulate tax return preparers and refund anticipation payment arrangements.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
To regulate tax return preparers and refund anticipation payment arrangements.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
Cosmetic Supply Chain Transparency Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntington's Disease Disability Insurance Access Act of 2021
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntington's Disease Disability Insurance Access Act of 2021
American Innovation and R&D Competitiveness Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
American Innovation and R&D Competitiveness Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
American Innovation and R&D Competitiveness Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
American Innovation and R&D Competitiveness Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
Huntington’s Disease Disability Insurance Access Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Huntington’s Disease Disability Insurance Access Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Huntington’s Disease Disability Insurance Access Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Huntington’s Disease Disability Insurance Access Act of 2021
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
To regulate tax return preparers and refund anticipation payment arrangements.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
To regulate tax return preparers and refund anticipation payment arrangements.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
To regulate tax return preparers and refund anticipation payment arrangements.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
To regulate tax return preparers and refund anticipation payment arrangements.
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Food and Drug Amendments of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Food and Drug Amendments of 2022
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
H. Res. 742- AADC Deficiency Awareness Day
Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
H. Res. 742- AADC Deficiency Awareness Day
Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
H. Res. 742- AADC Deficiency Awareness Day
Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
H. Res. 742- AADC Deficiency Awareness Day
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Creating Hope Reauthorization Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Drug development, review and pricing related issues; Issues related to healthcare and to the COVID-19 pandemic; H.R. 4439 - Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program - Section 908 of the Food and Drug Administration Safety and Innovation Act (FDASIA), which added section 529 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
Creating Hope Reauthorization Act
Client: PTC THERAPEUTICS, INC. · Firm: PTC THERAPEUTICS, INC.
Drug development, review and pricing related issues; Issues related to healthcare and to the COVID-19 pandemic; H.R. 4439 - Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program - Section 908 of the Food and Drug Administration Safety and Innovation Act (FDASIA), which added section 529 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2024 · first_quarter · 1A
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2024 · second_quarter · 2A
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2024 · first_quarter · 1A
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2024 · second_quarter · Q2
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2024 · first_quarter · Q1
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · fourth_quarter · 4A
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · third_quarter · 3A
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to access to medically necessary foods Issues related to rare disease diagnosis and testing Issues related to newborn screening Issues related to alternative funding programs
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations Issues related to the Labor, Health and Human Services, and Education appropriations
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · second_quarter · 2A
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · first_quarter · 1A
Issues related to the Orphan Drug Tax Credit; H.R. 1304 -American Innovation and R&D Competitiveness Act of 2021
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntington's Disease Disability Insurance Access Act of 2021
H. Res. 742- AADC Deficiency Awareness Day
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · fourth_quarter · Q4
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · third_quarter · Q3
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to access to medically necessary foods Issues related to rare disease diagnosis and testing Issues related to newborn screening Issues related to alternative funding programs
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations Issues related to the Labor, Health and Human Services, and Education appropriations
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · second_quarter · Q2
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2023 · first_quarter · Q1
H. Res. 742- AADC Deficiency Awareness Day
Issues related to the Orphan Drug Tax Credit; H.R. 1304 -American Innovation and R&D Competitiveness Act of 2021
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2022 · fourth_quarter · 4A
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
H. Res. 742- AADC Deficiency Awareness Day
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2022 · third_quarter · 3A
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2022 · fourth_quarter · Q4
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
H. Res. 742- AADC Deficiency Awareness Day
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2022 · third_quarter · Q3
H. Res. 742- AADC Deficiency Awareness Day
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2022 · second_quarter · Q2
Issues related to FDA and drug development; Accelerated Approval Pathway; Orphan Drug Tax Credit
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Issues relating to the adoption of value-based payment arrangements.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2022 · first_quarter · Q1
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Issues related to FDA and drug development; Accelerated Approval Pathway; Orphan Drug Tax Credit
Issues relating to the adoption of value-based payment arrangements.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2021 · fourth_quarter · 4A
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Issues relating to the adoption of value-based payment arrangements.
Issues related to drug development and the FDA; Issues related to COVID-19 therapies.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2021 · first_quarter · 1A
Issues relating to the adoption of value-based payment arrangements.
Issues related to drug development and the FDA; Issues related to COVID-19 therapies.
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2021 · fourth_quarter · Q4
Issues related to drug development and the FDA; Issues related to COVID-19 therapies.
Issues relating to the adoption of value-based payment arrangements.
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2021 · third_quarter · Q3
Issues related to drug development and the FDA; Issues related to COVID-19 therapies.
Issues relating to the adoption of value-based payment arrangements.
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2021 · second_quarter · Q2
Issues relating to the adoption of value-based payment arrangements.
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Issues related to drug development and the FDA; Issues related to COVID-19 therapies.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2021 · first_quarter · Q1
Awareness of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
Issues relating to the adoption of value-based payment arrangements.
Issues related to drug development and the FDA; Issues related to COVID-19 therapies.
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2020 · fourth_quarter · Q4
Drug development, review and pricing related issues; Issues related to healthcare and to the COVID-19 pandemic; H.R. 4439 - Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program - Section 908 of the Food and Drug Administration Safety and Innovation Act (FDASIA), which added section 529 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
Biopharmaceutical therapies for rare pediatric diseases
Biopharmaceutical therapies for rare pediatric diseases
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2020 · third_quarter · Q3
Drug development, review and pricing related issues; Issues related to healthcare and to the COVID-19 pandemic; H.R. 4439 - Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program - Section 908 of the Food and Drug Administration Safety and Innovation Act (FDASIA), which added section 529 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
Biopharmaceutical therapies for rare pediatric diseases
Biopharmaceutical therapies for rare pediatric diseases
Filing targets: HOUSE OF REPRESENTATIVES
PTC THERAPEUTICS, INC. via PTC THERAPEUTICS, INC.
2020 · third_quarter · RR
Bio pharmaceutical therapies for rare pediatric diseases; Drug development, review and pricing; Issues relating to healthcare and COVID-19 pandemic; Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program Innovation Act (FDASIA)
Bio pharmaceutical therapies for rare pediatric diseases; Drug development, review and pricing; Issues relating to healthcare and COVID-19 pandemic; Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program Innovation Act (FDASIA)
Bio pharmaceutical therapies for rare pediatric diseases; Drug development, review and pricing; Issues relating to healthcare and COVID-19 pandemic; Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program Innovation Act (FDASIA)
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 7384 - Creating Hope Reauthorization Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations Issues related to the Labor, Health and Human Services, and Education appropriations
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to access to medically necessary foods Issues related to rare disease diagnosis and testing Issues related to newborn screening Issues related to alternative funding programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to access to medically necessary foods Issues related to rare disease diagnosis and testing Issues related to newborn screening Issues related to alternative funding programs
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations Issues related to the Labor, Health and Human Services, and Education appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations Issues related to the Labor, Health and Human Services, and Education appropriations
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to access to medically necessary foods Issues related to rare disease diagnosis and testing Issues related to newborn screening Issues related to alternative funding programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to access to medically necessary foods Issues related to rare disease diagnosis and testing Issues related to newborn screening Issues related to alternative funding programs
Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act Issues related to the Orphan Drug Tax Credit
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations Issues related to the Labor, Health and Human Services, and Education appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntington's Disease Disability Insurance Access Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H. Res. 742- AADC Deficiency Awareness Day
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to the adoption of value-based payment arrangements; H.R. 7389 - MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Orphan Drug Tax Credit; H.R. 1304 - American Innovation and R&D Competitiveness Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE